Amarin highlights key data presented at AHA 2022 on VASCEPA/VAZKEPA

Amarin highlighted key data presented at the American Heart Association, AHA, 2022 Scientific Sessions relevant to VASCEPA/VAZKEPA and patient care. Important data at the meeting included RESPECT-EPA, A Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy – Statin and Eicosapentaenoic Acid and PROMINENT, Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes Study. The RESPECT-EPA clinical trial is an independent study funded by the Japanese Heart Foundation. Importantly, the study achieved a borderline statistical significance with a 21.5% reduction in the primary composite endpoint measuring cardiovascular risk and achieved a statistically significant 26.6% reduction in the secondary composite endpoint of RESPECT-EPA. In addition, a post-hoc analysis conducted by the investigators to control for attained EPA levels yielded a statistically significant 27.5% reduction in the primary endpoint. "We are very encouraged by the totality of these data presented at AHA 2022, as they further underscore the clinical and therapeutic value of VASCEPA/VAZKEPA for clinicians and tens of millions of patients globally," said Nabil Abadir, MB. CH.B., SVP, Chief Medical Officer and Head of Global Medical Affairs, Amarin. "Clinicians should make the best choice possible for their patients and should have confidence in VASCEPA as a proven treatment option on top of statins to reduce CV risk and to help optimize treatment in appropriate high-risk patients."